The Impact of Posthepatectomy Liver Failure on the Recurrence of Hepatocellular Carcinoma

2013 ◽  
Vol 38 (1) ◽  
pp. 150-158 ◽  
Author(s):  
Kohta Iguchi ◽  
Etsuro Hatano ◽  
Kenya Yamanaka ◽  
Shiro Tanaka ◽  
Kojiro Taura ◽  
...  
2015 ◽  
Vol 32 (3) ◽  
pp. 173-180 ◽  
Author(s):  
Shintaro Kuroda ◽  
Hirotaka Tashiro ◽  
Tsuyoshi Kobayashi ◽  
Masakazu Hashimoto ◽  
Yoshihiro Mikuriya ◽  
...  

Background/Aims: Coagulopathy can cause disseminated intravascular coagulation and posthepatectomy liver failure. Posthepatectomy liver failure predicts a poor prognosis after hepatectomy for hepatocellular carcinoma. Although antithrombin III reduces hypercoagulation, the impact of postoperative antithrombin III administration remains unknown. The aim of this study was to determine whether postoperative antithrombin III administration protects against the development of coagulation disorders. Methods: Data from 164 patients who received antithrombin III and 169 who did following curative hepatectomy for hepatocellular carcinoma were retrospectively collected and analyzed. To overcome bias due to different distributions of covariates for the two groups, a one-to-one match was created using propensity score analysis. After matching, patient outcomes were analyzed. Results: A multivariate analysis of the whole group revealed that antithrombin III activity of <50% on postoperative day 1 was an independent risk factor for posthepatectomy liver failure. After one-to-one matching, the rate of posthepatectomy liver failure was significantly lower in the AT-III-treated group than in the non-AT-III-treated group (16.3% (7/43) vs. 44.2% (19/43), p < 0.01). Conclusions: Antithrombin III may attenuate posthepatectomy liver failure in hepatocellular carcinoma, possibly by suppressing coagulopathy.


HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S159
Author(s):  
Y. Uemoto ◽  
K. Taura ◽  
T. Nishio ◽  
Y. Kimura ◽  
N. Nam ◽  
...  

Medicine ◽  
2019 ◽  
Vol 98 (18) ◽  
pp. e15458 ◽  
Author(s):  
Wei Peng ◽  
Xiao-Yun Zhang ◽  
Chuan Li ◽  
Tian-Fu Wen ◽  
Lv-Nan Yan ◽  
...  

2018 ◽  
Vol 59 (1-2) ◽  
pp. 12-22 ◽  
Author(s):  
Ikuo Nakamura ◽  
Yuji Iimuro ◽  
Seikan Hai ◽  
Yuichi  Kondo ◽  
Etsuro Hatano ◽  
...  

Background: Posthepatectomy liver failure (PHLF) was recently defined with the corresponding recommendations as follows: grade A, no change in clinical management; grade B, clinical management with noninvasive treatment; and grade C, clinical management with invasive treatment. In this study, we identified the risk factors for grade B and C PHLF in patients with hepatocellular carcinoma (HCC). Methods: Of 339 HCC patients who underwent curative hepatic resection, 218 were included for analysis. The LHL15 index (uptake ratio of the liver to that of the liver and heart at 15 min) was measured by 99m Tc-GSA (99m technetium-labelled galactosyl human serum albumin); remnant LHL15 was calculated as LHL15 × [1 − (resected liver weight − tumor volume)/whole liver volume without tumor]. Results: A total of 163 patients were classified as having no PHLF, whereas 17, 37, and 1 patient had PHLF grade A, B, and C, respectively. There were significant differences in indocyanine green R15, serum albumin, prothrombin time, Child-Pugh classification, LHL15 and remnant LHL15 between patients with grades B/C PHLF and patients with grade A or no PHLF. Only remnant LHL15 was identified as an independent risk factor for grades B/C PHLF (p = 0.023), with a cut-off value of 0.755. Conclusions: Remnant LHL15 was an independent risk factor for grades B/C PHLF. Patients with impaired remnant LHL15 value of <0.755 should be carefully monitored for PHLF.


Medicine ◽  
2019 ◽  
Vol 98 (15) ◽  
pp. e15168
Author(s):  
Ze-Qun Zhang ◽  
Bo Yang ◽  
Heng Zou ◽  
Li Xiong ◽  
Xiong-Ying Miao ◽  
...  

2017 ◽  
Vol 265 (6) ◽  
pp. 1201-1208 ◽  
Author(s):  
Yukihiro Okuda ◽  
Kojiro Taura ◽  
Kenji Yoshino ◽  
Yoshinobu Ikeno ◽  
Takahiro Nishio ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document